AstraZeneca: severe asthma drug meets primary endpoint
(CercleFinance.com) - AstraZeneca and its US partner Amgen said on Tuesday that their experimental severe asthma treatment has achieved its primary endpoint in a Phase 3 trial.
The drugmaker said that tezepelumab, plus standard of care, showed a statistically significant and clinically meaningful reduction in the asthma exacerbation rate over 52 weeks in the overall patient population, compared to placebo when added to inhaled corticosteroids.
The trial also met the primary endpoint in patients with low levels of eosinophils, AstraZeneca said, which also pointed out that tezepelumab was "very well tolerated" in patients.
Severe asthma, which is estimated to affect approximately 34 million people worldwide, sees patients continue to experience symptoms and frequent exacerbations despite the use of high-dose asthma controllers.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The drugmaker said that tezepelumab, plus standard of care, showed a statistically significant and clinically meaningful reduction in the asthma exacerbation rate over 52 weeks in the overall patient population, compared to placebo when added to inhaled corticosteroids.
The trial also met the primary endpoint in patients with low levels of eosinophils, AstraZeneca said, which also pointed out that tezepelumab was "very well tolerated" in patients.
Severe asthma, which is estimated to affect approximately 34 million people worldwide, sees patients continue to experience symptoms and frequent exacerbations despite the use of high-dose asthma controllers.
Copyright (c) 2020 CercleFinance.com. All rights reserved.